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A B S T R A C T 
Introduction: Immunoglobulin G4–related disease 
remains an under-recognised and evolving disease. 
Local data are sparse and previous publications have 
been limited to individual case reports or case series 
only. We conducted this study to review the clinical 
features, treatment practices, and factors associated 
with multisystem involvement in Hong Kong. 
We described the clinical features and treatment 
modalities of the largest cohort of immunoglobulin 
G4–related disease in our locality thus far.
Methods: We retrospectively evaluated all patients 
with immunoglobulin G4–related disease between 
January 2003 and December 2015 in Queen Mary 
Hospital and combined this with patient data 
extracted from previous local publications. We 
analysed the clinical features, treatment practices, 
and factors associated with the number of organ 
systems involved.
Results: A total of 104 patients (55 from Queen 
Mary Hospital and 49 from literature review) were 
identified. Patients were predominantly older men 
(mean [standard deviation] age, 61.9 [12.7] years; 
male-to-female ratio=3:1) and 94.4% had elevated 
pre-treatment serum immunoglobulin G4 levels. 
Hepatobiliary and pancreatic system (40.4%), 
salivary gland (33.7%), lymph node (29.8%), and 
eye (19.2%) were the most common organ systems 
involved. Lymphadenopathy was associated with 
glucocorticoid use (odds ratio=2.65; 95% confidence 
interval, 1.08-6.54; P=0.034). Pre-treatment 
serum immunoglobulin G4 levels correlated with 
the number of organ systems involved (ß=0.347; 
P=0.004) and, specifically, more associated with 
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New knowledge added by this study
• Hepatobiliary and pancreatic system, salivary gland, lymph node, and eye were the most common organ 
systems involved in immunoglobulin (Ig) G4–related disease in Hong Kong.
• Pre-treatment serum IgG4 levels were associated with salivary gland involvement and multisystem disease.
• Glucocorticoids were most frequently used, but local experience with other immunomodulatory agents was 
limited and varied across different centres.
Implications for clinical practice or policy
• Serum IgG4 should be used for disease prognostication and monitoring of treatment response.
• Salivary gland involvement should be screened in patients with IgG4-related disease, especially in the presence 
of higher level of serum IgG4.
• Future studies on treatment strategies within the contexts of different epidemiology and patient characteristics 
are urgently needed.
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ORIGINAL ARTICLECME
patients having salivary gland involvement than 
those without (mean, 1109 mg/dL vs 599 mg/dL; 
P=0.012). 
Conclusion: We identified pre-treatment serum 
immunoglobulin G4 to be associated with 
multisystem disease, especially with salivary gland 
involvement, highlighting its potential for disease 
prognostication and monitoring. Increased physician 
awareness and multidisciplinary efforts are required 
for early diagnosis and optimal management of this 
masquerading disease.
This article was 
published on 1 Sep 
2017 at www.hkmj.org.
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香港免疫球蛋白G4相關性疾病：臨床特徵、 
治療方法以及與多系統疾病的關聯
李曦、高君龍、何紫筠、劉欐、曾敬賢、張丹圖、 
梁偉強、劉澤星
引言：免疫球蛋白G4（IgG4）相關性疾病不斷進化，可惜仍然未被
廣泛認識。有關IgG4相關性疾病的本地數據較少，出版的文獻亦僅限
於個別病例報告或病例系列。本研究旨在回顧此疾病的臨床特徵和治
療方法，以及探討與香港患者多個受影響組織和器官相關的因素。這
是迄今有關IgG4相關性疾病最大型的本地隊列研究，我們針對患者的
臨床表現及治療方式加以描述。
方法：回顧分析2003年1月至2015年12月期間瑪麗醫院內所有IgG4相
關性疾病患者，將他們與過往本地出版文獻取得的患者資料結合。並
分析此疾病的臨床特徵和治療方法，以及與多個受影響組織和器官相
關的因素。
結果：研究了共104例（瑪麗醫院55例，文獻綜述49例）。患者多數
為年長男性（平均〔標準差〕年齡：61.9〔12.7〕歲；男女比例為
3：1），有94.4%的患者治療前血清IgG4水平升高。最常見受影響的
器官有肝膽和胰腺（40.4%）、唾液腺（33.7%）、淋巴結（29.8%）
和眼部（19.2%）。淋巴結病與使用糖皮質激素有關（比值比=2.65；
95%置信區間1.08-6.54；P=0.034）。治療前血清IgG4水平與受影響
的器官數目相關（ß=0.347；P=0.004），尤其與唾液腺受影響相關
（唾液腺受影響患者與非患者的平均IgG4水平：1109 mg/dL比599 
mg/dL；P=0.012）。
結論：本研究發現治療前血清IgG4水平與多系統疾病相關，尤其是唾
液腺，可見治療前血清IgG4水平可作為對此疾病的預後和監測。增加
醫生對此病的認識和跨專科參與是針對此疾病的早期診斷和最佳管理
的關鍵。
Introduction
Immunoglobulin (Ig) G4–related disease (IgG4-RD) 
is a systemic immune-mediated disease unifying 
what were previously considered to be unrelated 
individual organ disorders. This characteristic 
fibroinflammatory condition continues to be 
increasingly recognised but is still an evolving 
concept. The disease, IgG4-RD, was first described 
in 2003 when extra-pancreatic lesions with IgG4-
positive plasmacytic infiltration were identified 
in patients with autoimmune pancreatitis (now 
known as IgG4-related pancreatitis).1 Involvement 
of almost every anatomical site has been reported 
since. In addition to IgG4-related hepatobiliary 
disease, other examples of previous disease entities 
now under the diagnostic umbrella of IgG4-RD 
include Riedel’s thyroiditis, Ormond’s disease 
(idiopathic retroperitoneal fibrosis), Mikulicz’s 
disease (lymphoepithelial sialadenitis), Küttner’s 
tumour (chronic sclerosing sialadenitis), and other 
‘idiopathic’ pseudotumours.2 Regardless of the organ 
involved, patients share similar clinical, serological, 
and histopathological features.2,3 According to 
the ‘comprehensive diagnostic criteria for IgG4-
RD’, the diagnosis of IgG4-RD is based on the 
constellation of clinical, serological and, especially, 
histopathological findings.4 The recommended 
cut-off value for serum IgG4 level is >135 mg/dL. 
The characteristic histopathological findings include 
dense lymphoplasmacytic infiltrates, ‘storiform’ 
or swirling fibrosis, and obliterative phlebitis. 
Immunostaining for IgG4 should show >10 IgG4-
positive plasma cells per high-power field and an 
IgG4-positive–to–IgG-positive ratio (IgG4:IgG) 
plasma cell ratio of >0.4. 
 Despite continued advances in our 
understanding of the disease and the various 
multinational guidance now available,4,5 few studies 
have examined factors to predict disease severity 
or disease prognostication. The bulk of IgG4-RD–
related research originates from Caucasian or 
Japanese studies, and local regional data are sparse. 
Publications from Hong Kong have been limited 
to individual case reports or case series only. In 
this study, we performed a retrospective review 
of all our IgG4-RD patients between January 2003 
and December 2015. To the best of our knowledge, 
this is the largest cohort reported in our locality 
at the time of writing. By combining our data with 
all other available publications from Hong Kong, 
we examined the clinical features and treatment 
practices of IgG4-RD, as well as its clinical factors 
associated with multisystem involvement.
Methods
Retrospective study at Queen Mary Hospital
All available case records of IgG4-RD patients 
from Queen Mary Hospital—under the care of the 
Hong Kong West Cluster serving a population of 
0.53 million—between January 2003 and December 
2015 were reviewed. Cases were identified by 
the compilation of various databases of multiple 
specialist divisions (Rheumatology and Clinical 
Immunology, Gastroenterology and Hepatology, 
Otorhinolaryngology–Head and Neck Surgery, and 
Hepatobiliary and Pancreatic Surgery), in addition 
to cluster-wide screening of all patients with 
laboratory requests for serum IgG4 within the study 
period. Case records were reviewed according to 
the ‘comprehensive diagnostic criteria for IgG4-RD’ 
and all patients with definite, probable, or possible 
IgG4-RD were recruited.4 In accordance with these 
criteria, patients could also be diagnosed with a 
definite diagnosis of IgG4-RD if they fulfilled organ-
specific criteria.6 
 All data were extracted from patient records, 
including sex, age (at onset), organ manifestations, 
pre-treatment serum IgG4 and IgG levels, 
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pathology reports, and treatment modalities. 
Organ manifestations were classified into bone, 
central nervous system (CNS), hepatobiliary and 
pancreatic (HBP) system, lung, lymph node, eye 
(including lacrimal gland, extraocular muscles, 
and other intraorbital involvement), renal system, 
retroperitoneum, salivary glands (parotid and 
submandibular glands), and skin/soft tissue 
involvement. Treatment modalities were classified 
into surgical intervention (including resection and 
other mechanical interventions such as biliary or 
ureteric stenting), use of glucocorticoids (GCs), or 
other specified immunomodulatory therapy. This 
study was done in accordance with the principles 
outlined in the Declaration of Helsinki. Clinicians 
involved in data extraction were unaware of the 
studied associations. 
Literature review of existing local 
publications
We searched PubMed, PubMed Central, and 
MEDLINE databases without language restrictions 
from 1 January 2003 to 31 December 2016 using the 
terms ‘Hong Kong’ and ‘immunoglobulin G4’ or ‘IgG4’ 
or ‘IgG4-related disease’ or ‘IgG4-associated disease’ 
or ‘IgG4 sclerosing disease’. All patient data available 
from local IgG4-RD publications were reviewed 
against the ‘comprehensive diagnostic criteria for 
IgG4-RD’4 and extracted for analysis. Patients from 
publications originating from Queen Mary Hospital, 
who were already present in our database, were 
excluded. Parallel with the retrospective analysis, 
data regarding patients’ age, organ manifestations, 
pre-treatment serum IgG4 and IgG levels, pathology 
reports, treatment modalities, and medication 
regimens were recorded. Clinicians involved in 
data extraction were unaware of the studied 
associations.
Statistical analysis 
Potential factors associated with multisystem 
disease, reflected by the number of involved organ 
systems, were investigated. Univariate analysis was 
performed first using the independent samples 
t-test to compare categorical variables (such as sex) 
and linear regression was used to compare between 
continuous variables (such as age). Variables with a P 
value of ≤0.1 from univariate analysis were included 
in a multivariate linear regression to determine which 
were independently associated with the number 
of involved organ systems. The two-sided Fisher’s 
exact test was used to evaluate the association 
between treatment modalities and presence of organ 
manifestations. A P value of <0.05 was considered 
statistically significant. Statistical Package of the 
Social Sciences (Windows version 20.0; IBM Corp, 
Armonk [NY], US) was used for all analyses. The 
Venn diagram was created using jvenn.7
Results
Demographics, clinical features, and 
treatment modalities
Between January 2003 and December 2015, a 
total of 55 patients with IgG4-RD were identified 
at Queen Mary Hospital. Patients were under 
the care of a variety of medical and surgical 
subspecialties, including Rheumatology and Clinical 
Immunology, Gastroenterology and Hepatology, 
Otorhinolaryngology–Head and Neck Surgery, and 
Hepatobiliary and Pancreatic Surgery, in addition to 
multidisciplinary care between other departments 
and disciplines. Baseline demographics, clinical 
features, and treatment modalities are summarised 
in Table 1.8-21 Pre-treatment serum IgG4 level, 
total IgG level, and IgG4:IgG ratio were available 
for 48, 43, and 43 patients, respectively. A total 
of 46/48 (95.8%) patients had a serum IgG4 level 
of >135 mg/dL, and 39/43 (90.7%) patients had a 
IgG4:IgG ratio of >8%. Of the 55 patients, 40 (72.7%) 
had histopathological confirmation, of which 32 
samples had immunohistochemical staining with 
anti-IgG4 monoclonal antibodies. All treatment 
modalities were primarily used for the treatment 
of IgG4-RD except for one patient who was treated 
with COPP chemotherapy (cyclophosphamide, 
vincristine, procarbazine, and prednisone) because 
of concomitant lymphoma. Of the patients, 19 
(34.5%) underwent surgical treatment, including 
sialoadenectomy (n=7), pancreaticoduodenectomy 
(n=6), orbitotomy (n=2), cholecystectomy (n=2), 
and excision of musculoskeletal lesions (n=2).
 We identified an additional 49 IgG4-RD 
patients from 11 published case reports and case 
series from Hong Kong.8-18 Only those reporting 
pre-treatment serum IgG4 and IgG levels were 
included in our study. Treatment modalities were 
not reported in four patients. A summary of patient 
demographics, clinical features, and treatment 
modalities is shown in Table 2.8-18 
 As a result, a total of 104 patients were identified 
from Queen Mary Hospital and literature review. For 
patients with pre-treatment results available, 68/72 
(94.4%) patients had a serum IgG4 level of >135 
mg/dL, and 58/63 (92.1%) patients had an IgG4:IgG 
ratio of >8%. A summary of the demographics, 
clinical features, and treatment modalities in 
comparison to other cohorts is shown in Table 1.8-21 
The most common organ systems involved were HBP 
system (40.4%), salivary gland (33.7%), lymph node 
(29.8%), and eye (19.2%). A Venn diagram of these 
most common involved systems from the combined 
cohort is shown in the Figure.
Treatment practices: associations between 
organ manifestations and treatment 
modalities
The associations between various organ 
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manifestations and treatment modalities are shown 
in Table 3. Lymphadenopathy was associated with GC 
use (odds ratio [OR]=2.65; 95% confidence interval 
[CI], 1.08-6.54; P=0.034). Involvement of CNS was 
negatively associated with GC use (OR=0.12; 95% 
CI, 0.01-1.05; P=0.044).
Associations of serum immunoglobulin G4 
with multisystem disease and specific organ 
manifestations
Age, sex, pre-treatment serum IgG4, total IgG, and 
IgG4:IgG ratio were used in univariate analysis. Both 
age (P=0.021) and pre-treatment serum IgG4 levels 
TABLE	1.		Comparison	of	immunoglobulin	G4–related	disease	cohorts	from	Hong	Kong,8-18	Beijing	(Mainland	China),19	Massachusetts	(US),20	and	Milan	
(Italy)21
No. (%) of patients, mean ± SD (range), or median (IQR)
Current cohort, 
Hong Kong 
(n=55)
Combined cohort 
(current cohort + 
cases from literature 
review8-18), Hong Kong 
(n=104)
Beijing, Mainland 
China19 (n=118)
Massachusetts, 
US20 (n=125)
Milan, Italy21 (n=41)
Male 42 (76.4) 78 (75.0) 82 (69.5) 76 (60.8) 26 (63.4)
Age (years) 62 ± 12 (27-86) 62 ± 13 (26-89) 53 (19-80) 55 (24-83) 62 (55-67)
Serum IgG4 (mg/dL) 660.5 ± 488.1 
(116-2100) [n=48]
790 ± 717.5 (110-3450) 
[n=72]
1521.8 NA 284 (132-545)
Total IgG (mg/dL) 2202.1 ± 1108.6
(1080-5900) [n=43]
2611.1 ± 1436.7
(1080-7750) [n=69]
2300 NA NA
IgG4:IgG ratio 0.29 ± 0.18
 (0.04-0.65) [n=43]
0.31 ± 0.18 (0.04-0.70) 
[n=63]
0.38 NA NA
Histopathological confirmation 40 (72.7) 85 (81.7) 64 (54.2) 125 (100) 30 (73.2)
Organ involvement
Hepatobiliary and pancreatic 
system
26 (47.3) 42 (40.4) Autoimmune 
pancreatitis: 
45 (38.1); sclerosing 
cholangitis: 21 (17.8)
24 (19.2) Pancreas: 17 (41.5); 
biliary tree: 4 (9.8)
Salivary gland 24 (43.6) 35 (33.7) 76 (64.4) Submandibular: 
35 (28.0); parotid: 
21 (16.8)
8 (19.5)
Lymph node 8 (14.5) 31 (29.8) 77 (65.3) 34 (27.2) 5 (12.2)
Eye 8 (14.5) 20 (19.2) 60 (50.8) 28 (22.4) Orbit: 3 (7.3); 
lacrimal glands:  
2 (4.9)
Lung 7 (12.7) 7 (6.7) 32 (27.1) 22 (17.6) 1 (2.4)
Retroperitoneum 7 (12.7) 8 (7.7) 31 (26.3) 23 (18.4) 8 (19.5)
Renal system 2 (3.6) 3 (2.9) 29 (24.6) 15 (12.0) 1 (2.4)
Central nervous system 1 (1.8) 7 (6.7) NA NA 3 (7.3)
Skin/soft tissue 1 (1.8) 8 (7.7) 5 (4.2) 2 (1.6) NA
Other 1 (1.8)* 8 (7.7)† NA NA NA
No. of involved organ systems 1.7 (1-5) 1.6 (1-5) NA NA NA
Treatment
Glucocorticoids 37 (67.3) 57 (54.8) NA 64 (51.2) 36 (87.8)
Surgery 19 (34.5) 46 (44.2) NA NA NA
Other 12‡ 18§ NA NA NA
Abbreviations: COPP = cyclophosphamide, vincristine, procarbazine, and prednisone; Ig = immunoglobulin; IQR = interquartile range; NA = not available;  
SD = standard deviation
* Other organ systems include bone (n=1)
† Other organ systems include bone (n=1), breast (n=4), nasopharynx (n=1), pericardium (n=1), and prostate (n=1)
‡ Other treatments include azathioprine (n=6), mycophenolate mofetil (n=4), cyclophosphamide (n=1), and COPP (n=1)
§ Other treatments include azathioprine (n=8), mycophenolate mofetil (n=4), chlorambucil (n=2), cyclophosphamide (n=1), COPP (n=1), radiation 
therapy (n=2), and thalidomide (n=1); some patients received more than one form of treatment
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TABLE	2.		Characteristics	and	treatment	of	49	patients	with	IgG4-related	disease	in	Hong	Kong	based	on	literature	review8-18
Study Sex Age 
(years)
Organ manifestations IgG4 
(mg/dL)
IgG 
(mg/dL)
Histological 
confirmation
Treatment
Wong et al,8 2007 M 77 CNS, HBP 720 1330 Yes NA
Cheung and Lo,16 2008 M 59 HBP NA 1930 Yes Surgery
F 68 HBP NA 2890 Yes Surgery
M 69 HBP NA 4330 NA Biliary stenting only
M 63 HBP NA NA Yes GC
M 61 HBP 950 2180 Yes GC
Cheuk et al,15 2008 M 63 HBP, LN 180 NA Yes Surgery
M 59 HBP, LN NA 2290 Yes Surgery
F 68 HBP, LN NA 2887 Yes Surgery
M 77 LN, orbital, salivary NA 2830 Yes Surgery
M 67 LN, orbital 580 1660 Yes GC, azathioprine
M 71 LN, orbital, soft tissue NA 2533 Yes GC, chlorambucil, RT
M 47 HBP, LN 1383 5940 Yes GC
M 74 LN NA NA Yes Refused steroid therapy
M 73 LN, orbital, salivary 3200 5620 Yes GC
M 70 LN 2150 3667 Yes GC
M 69 LN 260 2606 Yes No treatment
M 37 LN NA 5790 Yes GC
Cheuk et al,14 2008 F 69 Orbital NA NA Yes NA
M 69 Nasopharynx NA NA Yes NA
M 60 Orbital, LN NA NA Yes NA
Cheuk et al,11 2009 F 48 Breast 350 NA Yes Surgery
F 51 Breast NA NA Yes Surgery
F 37 Breast, LN NA NA Yes Surgery
F 54 Breast NA NA Yes Surgery
Chan et al,10 2009 M 37 CNS NA NA Yes Surgery
Lui et al,9 2009 F 60 CNS NA NA Yes Surgery, RT
F 52 CNS NA NA Yes Surgery
M 45 CNS NA NA Yes Surgery
F 26 CNS NA NA Yes GC, thalidomide
Cheuk et al,12 2009 M 76 Orbital, soft tissue 1060 2340 Yes GC
F 74 LN, orbital, renal, salivary, soft tissue 1320 4540 Yes GC, chlorambucil
Chung et al,17 2010 M 51 HBP NA NA Yes Surgery
Cheuk et al,13 2010 M 42 Soft tissue NA NA Yes Surgery
M 60 LN, soft tissue 125 NA Yes GC
M 89 LN, orbital, salivary, soft tissue NA 2350 Yes Surgery, GC
M 71 LN, salivary, soft tissue NA NA Yes Surgery
Ng et al,18 2011 M 48 HBP 340 1440 Yes Surgery, GC
M 51 HBP 200 2240 Yes Surgery, GC, azathioprine
M 50 HBP, LN 800 2430 NA Surgery, GC
M 72 HBP, LN 920 4880 NA GC
M 50 HBP, LN, orbital, salivary 1450 2200 Yes GC
F 80 HBP 300 1490 Yes Surgery
M 67 Salivary, pericardium 1250 2850 Yes Surgery, GC
M 55 LN, orbital, salivary 400 3560 Yes GC
M 83 Salivary, prostate 3450 7750 Yes Surgery, GC
M 71 Salivary 480 NA NA Surgery
M 74 Orbital, salivary 3150 4520 Yes GC
F 77 Retroperitoneal 110 1400 Yes Surgery
Abbreviations: CNS = central nervous system; F = female; GC = glucocorticoids; HBP = hepatobiliary and pancreatic; Ig = immunoglobulin; LN = lymph 
node; M = male; NA = not available; RT = radiation therapy
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(P=0.020) significantly correlated with the number 
of involved organ systems in univariate analysis. 
Other variables did not reach statistical significance 
(data not shown). Only pre-treatment serum IgG4 
levels remained statistically significant in subsequent 
multivariate analysis (ß=0.347; P=0.004). For specific 
organ manifestations, pre-treatment serum IgG4 
level was more associated with patients having 
salivary gland involvement than those without (mean, 
FIG.		Venn	diagram	of	the	four	most	commonly	involved	
organ	systems	(n=89)
Abbreviation: HBP = hepatobiliary and pancreatic system
Salivary	gland
Salivary	glandHBP
Size	of	each	list
42
35 31
20
Lymph	node
Lymph	node
Eye
Eye
HBP
42
21
0
16 10
1
5
5
1
44
4
28
2
6
0 0
3
* Odds ratio = 2.65
† Odds ratio = 0.12
TABLE	3.		Associations	between	organ	manifestations	and	treatment	modalities
Organ manifestation No. (%) of patients
Glucocorticoid treatment Surgical intervention
Yes (n=57) No (n=47) P value Yes (n=46) No (n=58) P value
Hepatobiliary and pancreatic system 27 (47.3) 15 (31.9) 0.160 17 (37.0) 25 (43.1) 0.552
Salivary gland 21 (36.8) 14 (29.8) 0.331 15 (32.6) 20 (34.5) 1.000
Lymph node 22 (38.6) 9 (19.1) 0.034* 10 (21.7) 21 (36.2) 0.133
Eye 13 (22.8) 7 (14.9) 0.331 5 (10.9) 15 (25.9) 0.079
Lung 6 (10.5) 1 (2.1) 0.125 0 7 (12.1) 0.017
Retroperitoneum 6 (10.5) 2 (4.3) 0.289 2 (4.3) 6 (10.3) 0.297
Renal system 2 (3.5) 1 (2.1) 1.000 0 3 (5.2) 0.253
Central nervous system 1 (1.7) 6 (12.8) 0.044† 5 (10.9) 2 (3.4) 0.079
Skin/soft tissue 4 (7.0) 4 (8.5) 1.000 4 (8.7) 4 (6.9) 0.730
1109 mg/dL vs 599 mg/dL; P=0.012). No associations 
of serum IgG4 with other organ manifestations were 
found (P>0.1; data not shown). 
Discussion
In this study, we describe the clinical features and 
treatment practices of the largest cohort of IgG4-RD 
in our locality. After combination of our patients 
with all other published cases of IgG4-RD from 
Hong Kong, we analysed 104 cases comprising 
predominantly older men (mean age, 62 ± 13 years; 
male-to-female ratio=3:1), which is consistent with 
other reports.19-22 Over 95% of patients had serum 
IgG4 level of >135 mg/dL and an IgG4:IgG ratio of 
>8%. Although these cut-offs are often quoted in the 
diagnostic criteria for IgG4-RD,4,23 it is important to 
note that elevated serum IgG4 levels can be seen in 
a variety of other conditions such as malignancies, 
infections, or autoimmune disorders. Serum IgG4 
level and IgG4:IgG ratio alone have poor specificity 
and low positive predictive value. The specificity and 
positive predictive value of serum IgG4 and IgG4:IgG 
ratio have been reported to be approximately only 
0.6 and 0.3, respectively.24 Of note, 4/72 (5.6%) of our 
patients with biopsy-proven IgG4-RD had normal 
serum IgG4 levels (ie false negatives). The gold 
standard for diagnosis of IgG4-RD in most cases 
therefore remains biopsy with histopathological 
confirmation. Over 70% of patients in Queen Mary 
Hospital had positive histopathological confirmation, 
in comparison to 54.2% in a large Mainland Chinese 
cohort.19 Although this proportion increased to 
81.7% in the combined analysis, this could be an over-
estimation of real clinical practice with potential 
publication and selection bias from literature review. 
Similar to other reported populations, HBP system, 
salivary gland, lymph node, and eye were the most 
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common organ systems involved in both Queen 
Mary Hospital and the combined analysis. Although 
involvement of HBP system seemed more prevalent 
in the Queen Mary Hospital and Mainland China 
cohorts, the rate of HBP involvement is similar to 
other studies dedicated to IgG4-related hepatobiliary 
disease (approximately 40%-60%).25
 We also examined the treatment practices 
employed in our locality. Treatment of IgG4-RD 
is typically individualised because of substantial 
disease heterogeneity—even subclinical disease 
can lead to irreversible organ damage and not all 
manifestations require immediate treatment. For 
example, a watchful ‘wait and see’ approach may 
be an appropriate option for mild disease or after 
surgical debulking. However, there is currently 
no high-quality evidence-based guidance for the 
management of IgG4-RD and practices often vary 
significantly across different countries. In the 
combined analysis, GCs were the most popular 
treatment option and over half of the patients 
had received GCs either alone or in combination 
with other treatment modalities. In the combined 
analysis, use of GCs was significantly associated 
with lymphadenopathy, which may reflect their 
preferential use, especially in patients with systemic 
involvement. This is consistent with the general 
consensus and recommendations made by most 
experts because of their good initial efficacy.26 
The opposite was seen with an inverse association 
between CNS involvement and GC use. This was 
expected because most of these patients with CNS 
involvement had localised disease and the diagnosis 
of IgG4-RD was not readily established prior to 
surgical resection. Only one case was diagnosed by 
open brain biopsy and subsequently treated with 
GCs and thalidomide.9
 Local experience with other immuno-
modulatory agents was limited and choices for 
steroid-sparing agents varied between different 
centres. Conventional agents such as azathioprine, 
cyclophosphamide, methotrexate, mycophenolate, 
and tacrolimus have all demonstrated similar 
efficacy, although head-to-head comparisons are not 
available.27 B-cell depletion with rituximab has also 
gained much popularity in recent years and proven 
to be effective as induction and maintenance therapy, 
even without concomitant GCs.27,28 Nonetheless, we 
were unaware of any published experience with its 
use for IgG4-RD in Hong Kong at the time of writing. 
The advent of this ground-breaking treatment will 
likely require multidisciplinary expertise as well 
as further research, especially in the context of the 
high prevalence of chronic hepatitis B infection and 
subsequent risk of viral reactivation in Hong Kong. 
 Finally, we also recommend the utility of pre-
treatment serum IgG4 in disease prognostication 
and treatment monitoring. Pre-treatment serum 
IgG4 levels (but not IgG4:IgG ratios) significantly 
correlated with the number of organ systems 
involved. The correlation with age did not remain 
statistically significant after multivariate regression. 
Interestingly, Wallace et al20 also described elevated 
serum IgG4 levels associated with both age and 
number of organs involved, but analysis with 
multivariate regression was not reported in their 
study. Specifically, serum IgG4 levels also correlated 
with salivary gland involvement, but not with 
other individual organ systems. The reason for 
this particular correlation remains uncertain, but 
highlights the importance of screening for salivary 
gland involvement in all IgG4-RD patients, especially 
in the presence of higher serum IgG4 levels. 
 The main limitations of this study included its 
retrospective nature and restrictions of literature 
review. Limited clinical data were available and 
we were unable to determine or standardise for 
the disease duration of each patient. There were 
substantial missing data for some key variables, 
reducing the effective number of patients suitable 
for analysis. The nature of a literature review also 
harbours risk of publication or selection bias, 
although it was reassuring that findings from the 
combined analysis were similar to those obtained 
from Queen Mary Hospital. Some indefinite findings, 
such as lower prevalence of renal involvement, 
highlight the necessity of future prospective and 
multicentre studies. Specifically, we advocate the 
need for more uniform international diagnostic 
criteria and the establishment of a region-wide 
registry with longitudinal data collection. 
 In conclusion, we found that pre-treatment 
serum IgG4 significantly correlated with the number 
of organ systems involved, highlighting its potential 
for disease prognostication and guiding treatment. 
We also describe the clinical characteristics, 
treatment practices, and factors associated with 
multisystem disease in IgG4-RD in Hong Kong. 
There is vast disease and patient heterogeneity, 
making local research and expertise exchange 
imperative. Increased physician awareness and a 
multidisciplinary approach will be required for 
early diagnosis and optimal management of this 
masquerading disease. Further studies, especially 
focusing on treatment strategies within the contexts 
of different epidemiology and patient characteristics, 
are urgently needed.
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